Clinical Trial TitleA six-week, randomized, multicenter, double-blind, parallel, flexed- and fixed-dose study of MC01CI (Metadoxine Extended-Release) 700 mg and 1400 mg compared with placebo in adults and adolescents with fragile X syndrome
Clinical Trial Protocol Description:
The purpose of this study is to evaluate the effects of the investigational drug metadoxine extended release (MDX) on attention deficit symptoms. Attention deficit is a common symptom often associated with fragile X syndrome.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Be between ages 15 and 55.
- Be available for 84 days (12 weeks), including follow-up examinations.
This is a partial list of inclusion criteria.